Clear All
12159 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70377-0011-22 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2021 In Use
72237-0106-01 72237-0106 Selinexor XPOVIO 10.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Mar 10, 2025 In Use
70377-0012-23 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
00078-0715-91 00078-0715 Alpelisib PIQRAY Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00703-3125-08 00703-3125 Romidepsin Romidepsin Chemotherapy Enzyme Inhibitor HDAC Intravenous Aug 1, 2018 Oct 31, 2021 No Longer Used
72237-0101-01 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jul 10, 2019 In Use
00078-0681-66 00078-0681 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral Apr 1, 2016 In Use
72694-0617-60 72694-0617 Ivosidenib Tibsovo 250.0 mg/1 Chemotherapy Enzyme Inhibitor IDH1 Oral Oct 19, 2021 In Use
50242-0079-08 50242-0079 Inavolisib Itovebi 9.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K⍺ Oral Oct 14, 2024 In Use
72237-0105-01 72237-0105 Selinexor XPOVIO 80.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral Jan 5, 2026 In Use
16729-0223-61 16729-0223 temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug 13, 2018 In Use
63850-0128-02 63850-0128 Everolimus Everolimus 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jan 30, 2025 In Use
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous Apr 23, 2020 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug 25, 2011 In Use
00173-0913-01 00173-0913 Belantamab mafodotin Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Oct 23, 2025 In Use
00074-1055-01 00074-1055 Telisotuzumab Vedotin EMRELIS 100.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
51144-0020-01 51144-0020 ENFORTUMAB VEDOTIN PADCEV 20.0 mg/2mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec 18, 2019 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec 18, 2019 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sep 20, 2021 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug 5, 2020 Jun 30, 2024 No Longer Used
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sep 7, 2017 In Use
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 5.0 mg/mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov 14, 2022 In Use
65597-0801-01 65597-0801 Datopotamab Deruxtecan DATROWAY 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 Intravenous Jan 17, 2025 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug 18, 2017 In Use

Found 12159 results — Export these results